Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study

• Main Authors: Sammar Fathy Elhabal (Author), Mohamed A El-Nabarawi (Author), Nashwa Abdelaal (Author), Mohamed Fathi Mohamed Elrefai (Author), Shrouk A. Ghaffar (Author), Mohamed Mansour Khalifa (Author), Passant M. Mohie (Author), Dania S. Waggas (Author), Ahmed Mohsen Elsaid Hamdan (Author), Samar Zuhair Alshawwa (Author), Essa M. Saied (Author), Nahla A. Elzohairy (Author), Tayseer Elnawawy (Author), Rania A. Gad (Author), Nehal Elfar (Author), Hanaa Mohammed (Author), Mohammad Ahmad Khasawneh (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractCanagliflozin (CFZ) is a sodium-glucose cotransporter-2 inhibitor (SGLT2) that lowers albuminuria in type-2 diabetic patients, cardiovascular, kidney, and liver disease. CFZ is classified as class IV in the Biopharmaceutical Classification System (BCS) and is characterized by low permeabilit...